Combination therapies drives the Braf Kinase Inhibitors Market
 |
| Braf Kinase Inhibitors Market |
The global Braf Kinase Inhibitors
Market is estimated to be valued at US$ 1184.51 Mn in 2023 and is expected to
exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in
a new report published by Coherent Market Insights.
Market Overview:
Braf kinase inhibitors are oral
targeted therapy drugs used for treating metastasized melanoma. They work by
inhibiting B-Raf protein which is mutated in nearly 50% of melanoma cases. This
helps in stopping or slowing the growth of cancer cells with minimal side
effects.
Market key trends:
One of the major trends in the
Braf kinase inhibitors market is the introduction of combination therapies.
Earlier, Braf inhibitors were used as monotherapies but their effects were
found to be temporary. Recent research shows that using Braf inhibitors along
with MEK inhibitors provides better and longer treatment outcomes. This has led
to an increase in the development and approval of combination drug regimens
containing Braf and MEK inhibitors. For example, the combination of Encorafenib
and Binimetinib has shown significant improvement in progression-free survival
for advanced melanoma patients.
Segment Analysis
The global Braf kinase inhibitors
market is segmented into BRAF inhibitors and MEK inhibitors. Among them, BRAF
inhibitors held the largest market share in 2023 owing to the presence of a
wide range of approved drugs and higher adoption in melanoma treatment. Some of
the major approved BRAF inhibitors are Zelboraf (vemurafenib), Tafinlar
(dabrafenib) and Mekinist (trametinib).
Key Takeaways
The
global Braf kinase inhibitors market is expected to witness high growth,
exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence
of cancers like melanoma and lung cancer.
North America dominated the
global market in 2023 and is expected to maintain its dominance over the
forecast period. This is attributed to the growing cancer research, rising
healthcare expenditure and availability of advanced treatments.
Europe held the second largest
market share due to the growing geriatric population and increasing healthcare
funding by public and private players.
Asia Pacific is anticipated to
exhibit the fastest growth over the next few years owing to growing awareness,
increasing disposable income and improving healthcare infrastructure.
Key players operating in the Braf
kinase inhibitors market are F. Hoffmann-La Roche AG, Novartis International
AG, and Pfizer, Inc. F. Hoffmann-La Roche AG leads the market with its Zelboraf
product approved for melanoma treatment. Novartis AG follows next with its
Tafinlar and Mekinist products.
Read More
https://www.dailyprbulletin.com/braf-kinase-inhibitors-market-size-share-growth-outlook-2023/
Comments
Post a Comment